Loading...
NPI 1710645072 · Tulsa, OK · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Axiom Biogenomics LLC is a clinical medical laboratory provider located in Tulsa, Oklahoma. This profile covers 42 Medicare and 2 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Axiom Biogenomics LLC |
| Address | 7335 S Lewis Ave Ste 120 |
| City | Tulsa |
| State | OK |
| ZIP | 74136 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | December 3, 2021 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $1.5M |
| Medicaid | $0 |
AXIOM BIOGENOMICS LLC is a Clinical Medical Laboratory in TULSA, OK with an NPI enumerated on 2021-12-03 (~5 years ago). Its lifetime Medicare revenue is $1.5M while reported Medicaid revenue is $0, making its activity effectively single-payer Medicare by scale and tenure consistent with a relatively new entrant to Medicare billing.
Revenue concentration is high: the precomputed top 3 codes account for 47.1% of this provider's total Medicare revenue. The top three drivers are 81419 ($369.6K revenue, 26.5%), 81185 ($149.2K revenue, 10.7%), and 81325 ($138K revenue, 9.9%), indicating a narrow set of high-value tests that produce nearly half of Medicare receipts.
The code mix points to a specialized molecular diagnostics operation focused on genetic sequencing and single-gene analyses rather than broad clinical lab testing. High-revenue codes include a multi-gene genomic sequencing panel 81419 (epilepsy panel) and multiple single-gene full-sequence tests such as 81185 (CACNA1A), 81325 (PMP22), and 81302 (MECP2), consistent with a referral or niche genetic-testing lab serving neurology and hereditary disease indications.
Competitive standing across national Medicare peers is modest to typical for the provider's top CPTs: 81419 ranks #10 of 27 providers nationally (65th percentile), 81185 ranks #7 of 25 (75th percentile), and 81325 ranks #8 of 23 (68th percentile). These rank/percentile positions indicate above-minimal presence but not market leadership — AXIOM participates at a typical volume level compared with national specialty lab peers.
There are a handful of codes where AXIOM bills at higher-than-typical national percentiles, suggesting pockets of relative strength within its service mix. For example, 81400 ranks #6 of 38 providers nationally (86th percentile), 81329 ranks #7 of 26 (76th percentile), and 81192 ranks #8 of 27 (73rd percentile), which together indicate the provider has above-typical activity on certain Tier 2 molecular and specific-gene tests.
Operationally, the provider reports repeated, consistent claim volumes across many single-gene tests (multiple codes show 183 claims, and others show 180–183 claims), which suggests standardized testing workflows or panel-derived billing practices that yield high, repeatable volumes for a subset of assays. Examples with 183 claims include 81189, 81309, 81256, 81191, 81192, 81329, 81312, and 81271, reinforcing a pattern of batch or protocol-driven testing.
AXIOM also bills a mix that includes lower-paid but steady-volume tests, indicating breadth beyond only high-reimbursement panels. Notable lower-average-paid items in the top 25 include 87798 (315 claims, $34 avg paid/claim, $10.7K revenue) and 81256 (183 claims, $64 avg paid/claim, $11.7K revenue), which contribute modestly to Medicare revenue while reflecting ancillary infectious-agent or common genetic screenings.
Dependence on Medicare ($1.5M) with $0 in Medicaid revenue creates a concentrated payer mix and exposure to Medicare policy or rate changes. For analysts assessing commercial/Medicaid contracting or diversification, AXIOM appears to be primarily Medicare-focused today, which could affect negotiations or risk assessments for payers seeking broader multi-payer engagement.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
42 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 81419 | The lab analyst performs the technical lab test on a specimen such as blood to conduct a genomic sequence analysis panel. The test evaluates the genetic sequences of at least the 24 genes listed in… | 150 | $2,400 | $369.6K |
| 81185 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the calcium voltage–gated channel subunit alpha1 A gene, also called CACNA1A. | 180 | $830 | $149.2K |
| 81325 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the peripheral myelin protein 22, or PMP22, gene. | 180 | $750 | $138K |
| 81302 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the methyl CpG binding protein 2, or MECP2 gene. | 180 | $520 | $94.6K |
| 81309 | The lab analyst performs the technical lab test to analyze specific gene sequences of the phosphatidylinositol–4, 5–biphosphate 3–kinase, catalytic subunit alpha (PIK3CA) gene. | 180 | $270 | $49.2K |
| 81189 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the cystatin B gene (CSTB). | 180 | $270 | $48.7K |
| 81286 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the frataxin gene (FXN). | 180 | $270 | $48.7K |
| 81307 | The lab analyst performs the technical lab test on a specimen such as blood, to analyze the entire gene sequence for the partner and localizer of BRCA2 (PALB2) gene. | 70 | $660 | $47.1K |
| 81317 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the postmeiotic segregation increased 2 [S. cerevisiae], or PMS2 gene. | 70 | $660 | $45.7K |
| 81298 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the mutS homolog 6 [E. coli], or MSH6 gene. | 70 | $630 | $42.1K |
Showing 1–10 of 42
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 42 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
42 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 81419 | 2 | 10 | 150 | $2,400 | $427.1K |
| 87798 | 34 | 40 | 1,090 | $30 | $188.7K |
| 81185 | 1 | 10 | 70 | $830 | $81.8K |
| 81302 | 2 | 10 | 180 | $520 | $75.9K |
| 81325 | 1 | 10 | 50 | $760 | $71.9K |
| 87481 | 29 | 40 | 360 | $30 | $70.3K |
| 81238 | 2 | 10 | 100 | $590 | $60.6K |
| 81223 | 2 | 10 | 120 | $480 | $57.7K |
| 81249 | 2 | 10 | 70 | $590 | $41.1K |
| 81307 | 1 | 10 | 50 | $660 | $34.1K |
Showing 1–10 of 42
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
2 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 20 | $0 | $0 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 20 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Oklahoma providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Oklahoma median
2 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 52 | 50 | 330 | $80 | $238.7K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 27 | 30 | 370 | $20 | $60.1K |
Other providers in the same ZIP code as Axiom Biogenomics LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.